In the current state of cancer therapy, immune checkpoint inhibitors (ICIs), such as anti-PD-1, anti-PD-L1, and anti-CTLA4, have emerged as one of the most successful strategies in clinics and have used in the market to cure cancer [1]. This evidence concerns the gene CTLA4 and cancer.